Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

References

• Kawalec P, Kryst J, Mikrut A, Pilc A. Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials. PLoS ONE. Oct 2013;8(10):e76587.
   PubMed Web of Science ®Google Scholar
• de Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res. Jan 2010;85(1):75–90.10.1016/j.antiviral.2009.09.008
   PubMed Web of Science ®Google Scholar
• Jayaweera D, Dilanchian P. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data. Expert Opin Pharmacother. Dec 2012;13(18):2601–2612.10.1517/14656566.2012.742506
   PubMed Web of Science ®Google Scholar
• Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990;250(4986):1411–1413.10.1126/science.1701568
   PubMed Web of Science ®Google Scholar
• Joly V, Yeni P. Non-nucleoside reverse transcriptase inhibitors. Ann Med Interne (Paris). Jun 2000;151(4):260–267.
   PubMedGoogle Scholar
• Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract. Jan 2007;61(1):105–118.10.1111/j.1742-1241.2006.01146.x
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. Aug 2001;23(8):1296–1310.10.1016/S0149-2918(01)80109-0
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. Aug 2005;353(5):487–497.10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study. J Acquir Immune Defic Syndr. Dec 2006;43(Suppl 1):S127–S133.10.1097/01.qai.0000248349.25630.3d
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once‐daily antiretroviral regimens: a meta‐analysis. Clin Infect Dis. Feb 2009;48(4):484–488.10.1086/597429
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. May 2000;14(8):F77–F82.10.1097/00002030-200005260-00001
   PubMed Web of Science ®Google Scholar
• Macha S, Yong CL, MacGregor TR, et al. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol. Dec 2009;49(12):1417–1425.10.1177/0091270009344856
   PubMed Web of Science ®Google Scholar
• Macha S, Yong CL, Darrington T, et al. In vitro-in vivo correlation for nevirapine extended release tablets. Biopharm Drug Dispos. Dec 2009;30(9):542–550.10.1002/bdd.691
   PubMed Web of Science ®Google Scholar
• Battegay M, Arasteh K, Plettenberg A, et al. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Clin Ther. Sep 2011;33(9):1308–1320.10.1016/j.clinthera.2011.08.003
   PubMed Web of Science ®Google Scholar
• Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naïve HIV-1-infected patients. Antivir Ther. 2011;16(5):759–769.10.3851/IMP1803
   PubMed Web of Science ®Google Scholar
• Arasteh K, Ward K, Plettenberg A, et al. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1 infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med. Apr 2012;13(4):236–244.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. Oct 2008;9(8):563–608.
   PubMed Web of Science ®Google Scholar
• Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. Feb 2006;61(2):148–154.10.1111/bcp.2006.61.issue-2
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. Jun 2007;4(2):106–119.10.1016/S1550-8579(07)80025-8
   PubMed Web of Science ®Google Scholar
• Stöhr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13(5):675–685.
   PubMed Web of Science ®Google Scholar
• van der Leur MR, Burger DM, la Porte CJ, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. Oct 2006;28(5):650–653.10.1097/01.ftd.0000245681.12092.d6
   PubMed Web of Science ®Google Scholar
• de Maat MM, Nellen JF, Huitema AD, et al. Race is not associated with nevirapine pharmacokinetics. Ther Drug Monit. Aug 2004;26(4):456–458.10.1097/00007691-200408000-00018
   PubMed Web of Science ®Google Scholar
• Rowland LS, MacGregor TR, Campbell SJ, Jenkins R, Pearsall AB, Morris JP. Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. Sep 2007;856(1–2):252–260.10.1016/j.jchromb.2007.06.007
   PubMed Web of Science ®Google Scholar
• van Leth F, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses. Mar 2006;22(3):232–239.10.1089/aid.2006.22.232
   PubMed Web of Science ®Google Scholar
• Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res. Sep–Oct 2008;58(3–4):173–182.10.1016/j.phrs.2008.07.007
   PubMed Web of Science ®Google Scholar